Title : Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.

Pub. Date : 2020 Jul

PMID : 32147362






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 We evaluated the safety and anti-fibrotic effect of selonsertib, a selective inhibitor of ASK1, in patients with advanced fibrosis due to NASH. Selonsertib mitogen-activated protein kinase kinase kinase 5 Homo sapiens